Rosetta Genomics

Rosetta Genomics and UC Davis Researchers to Develop and Validate microRNA Biomarker to Predict Response to Neoadjuvant Chemotherapy in Bladder Cancer

June 28, 2011

PHILADELPHIA and REHOVOT, Israel, June 28, 2011 /PRNewswire/ – Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, announces it has entered into a collaboration with the University of California,  Davis (“UC Davis” or the “University”) to develop and validate a microRNA profile for muscle-invasive bladder cancer (MI-BC) that is […]

Read the full article →

Rosetta Genomics Announces Issuance of Additional U.S. Patent

May 9, 2011

Strengthens its Broad and Deep microRNA Intellectual Property for microRNA-based Diagnostics PHILADELPHIA and REHOVOT, Israel, May 9, 2011 /PRNewswire/ — Rosetta Genomics (NASDAQ: ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of […]

Read the full article →

Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its First Generation microRNA Diagnostic Tests

January 3, 2011

First Generation miRview® Tests Now Available to Residents of All 50 U.S. States REHOVOT, ISRAEL and PHILADELPHIA, PA–(Marketwire – January 3, 2011) – Rosetta Genomics, Ltd. (“Rosetta”) (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the New York State Department of Health (NYS DOH) has issued Rosetta Genomics a […]

Read the full article →

Rosetta Genomics Announces the Availability of Improved Tumor Classification Diagnostic

December 13, 2010

miRview® mets(2), a Second Generation Version of their miRview® mets Test Features an Expanded Panel of 42 Tumor Origin, and Improved Classifiers PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire – December 13, 2010) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics announces today the commercial availability of miRview® mets² (“miRview […]

Read the full article →

Rosetta Genomics Restructuring

October 5, 2010

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced a corporate restructuring that is expected to result in a 32% reduction in the Company’s monthly burn rate, thereby reducing annual operating expenses by approximately $4 million. Under the restructuring, Rosetta Genomics will eliminate 14 positions or nearly 20% […]

Read the full article →

Recent microRNA Press

September 3, 2010

Rosetta Genomics to Host Second Quarter 2010 Conference Call on Wednesday, September 8, 2010 REHOVOT, Israel & PHILADELPHIA, Sep 02, 2010 (BUSINESS WIRE) – Rosetta Genomics, Ltd. , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June […]

Read the full article →

A Busy Month in the Business of microRNA

June 30, 2010

BUSINESSWIRE – June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR) June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel […]

Read the full article →

Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Potential microRNA Drug Target for Mesothelioma

May 24, 2010

REHOVOT, Israel & PHILADELPHIA–(BUSINESS WIRE)–Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced today that the results of a joint study with the NYU Langone Medical Center were published on May 12th, 2010 in the online issue of The Journal of Biological Chemistry. The study “Pro-tumorigenic Effects of miR-31 […]

Read the full article →

microRNA Clinical News

March 29, 2010

Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis March 29, 2010 8:00 AM EDT – New Paper Published in Nature Biotechnology Reports Therapeutic Efficacy of Targeting miR-10b as a New Anti-Metastatic Agent – CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics Inc. today announced the […]

Read the full article →

microRNA of the week: microRNA-29

February 19, 2010

There are several groups making headlines that are studying the mir-29 family. Rosetta Genomics Headlines – Joint Study By Rosetta Genomics And NYU Langone Medical Center Identifies Single MicroRNA Biomarker For Prognosis Of Mesothelioma Patients Single microRNA exhibits potential to forecast outcomes of MPM  The results clearly demonstrate that higher levels of miR-29c* in MPM […]

Read the full article →